Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Henagliflozin Proline Tablets treatment

Phase 3Small molecule

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[3][1]

Indication

Geriatric PatientsNot yet recruiting

Geriatric PatientsPhase 3

Not yet recruiting

Timeline

Expected Milestones

Q3 2027

Post-ApprovalNot yet recruiting

Geriatric Patients

NCT07323381

Clinical

Trials by Indication[1]

Geriatric Patients1 trial

Effects of Henagliflozin Proline and Metformin XR on Body Composition in Geriatric Patients With Newly Diagnosed T2DM

Not yet recruiting·BBin Lu·Phase 4·NCT07323381·116 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Henagliflozin Proline Tablets treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Henagliflozin Proline Tablets treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Henagliflozin Proline Tablets treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bin Lu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: BBin Lu

Related News